Diagnose on
DAYZERO

Revolutionizing infectious disease diagnosis and treatment with genomic sequencing and machine learning to solve antibiotic resistance.

Featured NEWS

DZD Announces Completion of $16M Financing Round
This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
Read More
DZD Awarded SBIR Grant for Development of Microbiome Diagnostics
This award funds DZD's development of epiXact®FMT, a pharmacovigilance assay to enhance safety and efficacy in fecal microbiota transplant (FMT) clinical trials.
Read More
DZD Welcomes Healthcare Business Leader Gail Marcus to its Board
DZD announced that Gail Marcus has joined the company’s Board of Directors as an independent director
Read More

Public Health Crisis

Antibiotic resistance is an ongoing crisis that causes at least 700,000 global deaths annually. By 2050, this figure is expected to grow to 10 million. Patients can die of a severe infection like sepsis within hours, but current diagnostics for antibiotic resistance can take 2-5 days or never return a result at all. Physicians are left to treat using trial and error approaches based on limited information – the exact opposite of precision medicine.

Learn More

What We Do

DZD is developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment.

We are harnessing the power of the genome to build technologies that both precisely identify the species and provide the comprehensive antibiotic susceptibility / resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly. Faster treatment with the right antibiotic saves lives and reduces the cost and complications associated with extended episodes of care.

View Our Work

Rapid Response Partner

DZD is also developing technologies to help control HAIs (healthcare-associated infections), where antibiotic resistant organisms can be especially dangerous. Our rapid turnaround epiXact® service uses whole genome sequencing to provide infection control professionals with precise information on pathogen relatedness in less than 2 days, so they can make the right intervention decisions early and confidently.

Learn More